Drug Trial Radar · NCT03655483
Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma
Last checked: Nov 19, 2026Latest source record: Jun 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
85
Planned (sponsor's estimate)
Start
Aug 24, 2018
Primary completion
Apr 11, 2021
Study completion Apr 11, 2022
Sponsor
- Lead sponsor
- Guangzhou Gloria Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with refractory cHL. Patients will be treated with GLS-010
Conditions
- Classical Hodgkin's Lymphoma
Interventions
GLS-010Drug
Full-human anti-pd-1 monoclonal antibodies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: 2 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital & Institute
Beijing, China
Guizhou Cancer Hospital
Guiyang, Guizhou, China
Hunan Cancer Hospital
Changsha, Hunan, China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.